← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kalocyte, Inc.
Baltimore, MD
$5,936,105
Total funding
4
Grants
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,936,105 · 4
By mechanism
R44$3,043,060 · 1
R42$2,019,830 · 1
SB1$499,999 · 1
R43$373,216 · 1
Investigators at Kalocyte, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$1,050,000
R44 · FY2023 · HL
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$997,590
R44 · FY2024 · HL
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$995,470
R44 · FY2025 · HL
ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute$833,728
R42 · FY2018 · HL
ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute$788,480
R42 · FY2019 · HL
Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute)$499,999
SB1 · FY2021 · HL
ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute$397,622
R42 · FY2017 · HL
Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell$373,216
R43 · FY2020 · HL